NewAmsterdam Pharma Insider: CEO Louise Kooij Buys at a 70% Discount, Sells a Chunk Later – Is the Stock Undervalued?

Insider Activity at NewAmsterdam Pharma: A Close‑Read of Recent Deals

The latest Form 4 filed by Chief Accounting Officer Louise Kooij reveals a mixed bag of buys and sells on July 20, 2026, giving investors a window into the company’s internal confidence and cash‑flow needs.

1. What the July 20 Transaction Tells Us

On July 20, Kooij purchased 25 000 ordinary shares at $11.90 and 80 000 shares at $11.17, bringing her holdings to 129 353 shares. Later that day she sold 70 200 shares at a weighted average of $29.96 and 31 885 shares at $31.05, reducing her stake to 59 153 shares. The net effect—an overall purchase of roughly 49 200 shares—suggests a net long position in the company despite the heavy selling activity.

The buys occurred at about one‑third of the market price (the closing price on that day was $32.34), while the sales were near the current market level. This pattern is typical of insiders who maintain a long position while liquidating a portion of their holdings to meet liquidity needs or diversify portfolios. Importantly, Kooij’s purchases occurred at a price significantly below market, indicating a belief that the stock is undervalued.

2. Implications for Investors and the Company’s Outlook

Valuation signal: The 30‑plus percent discount between the purchase price and the market price signals a possible undervaluation, especially given NewAmsterdam Pharma’s robust pipeline of oral small‑molecule therapies for cardiovascular disease. If insiders are buying at such a discount, it could be a bullish sign for the broader market.

Cash‑flow considerations: The sizeable sell‑off later in the day may reflect the CFO’s need for liquidity, perhaps to fund ongoing clinical trials or regulatory filings. While this does not necessarily indicate distress, it does highlight the capital‑intensive nature of the biopharma sector.

Market sentiment: Social‑media sentiment for the day was neutral (-0) and buzz was low (0 % relative to average). Combined with the insider buying, the market appears cautiously optimistic but not overly exuberant. Investors should monitor whether the company’s earnings outlook or upcoming trial milestones materially change this stance.

3. Kooij Louise Frederika: A Transaction Profile

Kooij’s trading history over the past year shows a consistent pattern of buying at low prices and selling near or above the market average. Key observations:

• Early‑stage purchases: Kooij routinely buys when the stock is near $10–$12, often accompanied by restricted‑stock units that vest over time.
• Periodic sell‑offs: She sells in bursts, usually when the price hovers around $30–$32, sometimes taking a small profit margin.
• Option activity: She has exercised and sold option contracts, indicating a sophisticated use of derivatives to manage exposure.

This disciplined approach suggests a long‑term belief in NewAmsterdam Pharma’s pipeline and a strategy to maintain a substantial equity stake while managing liquidity.

4. Bottom Line for Investors

• Bullish nuance: Insider buying at a significant discount hints that Kooij—and by extension the board—believes the stock is undervalued.
• Neutral risk: The large sell‑off on the same day does not signal panic but reflects routine portfolio management.
• Watch for catalysts: Upcoming clinical data, regulatory approvals, or partnership announcements could trigger a sharper move.

In sum, the July 20 Form 4 offers a cautiously optimistic snapshot: insiders are buying at bargain prices while trimming positions when the market rises, a classic pattern for seasoned executives in a high‑growth biopharma. Investors looking for a long‑term bet on cardiovascular therapeutics may find this activity reassuring, provided they keep an eye on the company’s clinical timelines and regulatory milestones.